Top

Gepubliceerd in:

01-03-2009 | editorial

Primary prevention with ICDs, are we on the right track?

Auteurs: A. A. M. Wilde, T. A. Simmers

Gepubliceerd in: Netherlands Heart Journal | Uitgave 3/2009

Abstract

There is little doubt that the introduction of internal defibrillators (ICD) has saved many lives over the last two decades. Initially, ICD use was only studied and propagated in resuscitated patients, but from the mid-1990s onwards primary prevention studies have been conducted in patients with ischaemic and non-ischaemic cardiomyopathy and a left ventricular ejection fraction (LVEF) ≤30 to 35%.

vorige artikel Primary prevention by implantable cardioverter defibrillators: shock proof?

volgende artikel Infection after ICD implantation: operating room versus cardiac catheterisation laboratory

Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at risk for ventricular arrhythmia. Multi-center Automatic Defibrillator Implantation Trial Investigators. New Engl J Med 1996;335:1933–40.

Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl J Med 2002;346:877–83.

Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Sudden Cardiac Death in Heart Failure Trail (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med 2005;352:225–37.

Ferreira SW, Hauptman PJ. Implantation of cardiac defibrillators for primary prevention: a pendulum too far? Expert Rev Cardiovasc Ther 2008;6:1047–50.

Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol 2008;52:1111–21.

Myerburg RJ. Implantable Cardioverter-defibrillators after myocardial infarction. NEJM 2008;359:2245–53.

Bracke F, Dekker L, van der Voort P, Merjer A. Primary prevention with the ICD in clinical practise: not as straightforward as the guidelines suggest? Neth Heart J 2009;17:107–10.

Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association task force and the European Society of Cardiology committee for practice guidelines. J Am Coll Cardiol 2006;48:e247-306.

Epstein AE, Dimraco JP, Ellenbogen KAS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy for cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2008;51:2085–105.

10.

Goldenberg I, Vyas AK, Hall WJ, et al. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2008;51:288–96.

11.

Swindle J, Burroughs TE, Schnitzler MA, Hauptman PJ. Short-term mortality and costs associated with cardiac device implantation in patients hospitalized with heart failure. Am Heart J 2008;156:322–8.

12.

Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure. JAMA 2003;290:2581–7.

13.

Wilber DJ, Zareba W, Hall WJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 2004;109:1082–4.

14.

Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. NEJM 2004;351:2481–8.

15.

Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure or both. N Engl J Med 2005;352:2581–8.

16.

Dalal D, Arking D, Cheng A, Akar FG, Post W, Kao L, et al. CAPON alleles predict firings of ICD's implanted for primary prevention of sudden cardiac death [Abstract]. Circulation 2006;114: suppl:558–9.

17.

Reynolds MR, Cohen DJ, Kugelmass AD, et al. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverter-defibrillators. JACC 2006;47:2493–7.

18.

Remmelts H, Meine M, Loh P, Hauer RN, Doevendans PA, van Herwerden LA, et al. Infection after ICD implantation: operating room versus cardiac catheterisation laboratory. Neth Heart J 2009;17:95–100.

19.

Kleemann T, Becker T, Doenges K, et al. Annual rate of trans-venous defibrillation lead defects in implantable cardioverter-defibrillator over a period of >10 years. Circulation 2007;115:2474–80.

20.

Birnie, D. Farwell and M.S. Green et al. Accelerating risks of Fidelis lead fracture, Heart Rhythm 2008;5:1375–9.

21.

Hermanides RS, Ottervanger JP, Elvan A,RamdatMsierAR Life-threatening perforation of a defibrillation lead. Neth Heart J 2009;17:113–4.

Titel: Primary prevention with ICDs, are we on the right track?
Auteurs: A. A. M. Wilde
T. A. Simmers
Publicatiedatum: 01-03-2009
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Netherlands Heart Journal / Uitgave 3/2009
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI: https://doi.org/10.1007/BF03086225

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen

Andere artikelen Uitgave 3/2009

Infection after ICD implantation: operating room versus cardiac catheterisation laboratory

Towards a better risk stratification for sudden cardiac death in patients with structural heart disease

Life-threatening perforation of a defibrillation lead

The dawn of a new era in the struggle against sudden cardiac death

Primary prevention by implantable cardioverter defibrillators: shock proof?

Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest?